Nitchakan Darai. In Silico Screening of Chalcones against epstein-Barr Nuclear antigen 1 Protein in Epstein-Barr Virus (EBV). Master's Degree(Biotechnology). Chulalongkorn University. Office of Academic Resources. : Chulalongkorn University, 2017.
In Silico Screening of Chalcones against epstein-Barr Nuclear antigen 1 Protein in Epstein-Barr Virus (EBV)
Abstract:
Epstein-Barr Nuclear Antigen 1 (EBNA1), a crucial protein encoded by the Epstein-Barr virus (EBV), plays an important role in the replication and transcriptional regulator of EBV virus latent gene expression. Therefore, it is associated with several diseases especially human malignancies. The previous studies have demonstrated that chalcone derivatives can potentially inhibit the EBV virus. In this study, a series of designed chalcones were in silico screened toward EBNA1 using molecular docking. The docking results show that the interaction energies of 3a, 3b, 3d, 4g and 4h are better than those of the known anti-EBV agents, 1335528, 2122620 and 4-hydroxyderricin. The binding affinity predictions based on molecular mechanics generalized Born surface area (MM/GBSA) method show that chalcones 3a and 3b display significantly greater binding affinities than those of the three known compounds. Protein-ligand binding mainly through van der Waals (vdW) interaction. Furthermore, The principal component analysis (PCA) calculation reveals that the screened chalcone importantly induce the protein residues 476, 477, 480, 481, 485, 515, 516, 520, 579, 583, 586, 590 and 593 to become likely closer to ligand molecule. Altogether, the chalcones 3a and 3b might be served as a lead compound acting against EBNA1. Moreover, the results of pharmacophore modeling show that Everolimus, Azilsartan, Fluticasone, Estramustine, Cefditoren and Travoprost might be the potential candidate drugs acting against the EBNA1 target.